First AD

Second AD

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health Perspectives is a recurring content series published on MHE and Formulary Watch through print, digital and video avenues. The series focuses on updates around new real-world evidence/data and trends that stand to impact treatment guidelines, access decisions, and patient experience.

Population Health Perspectives

Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.


A Labeling Indication of SPMS Can Treat More Patients

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies EP8

Challenges Regarding Coverage for New SPMS Therapies

Evolving Treatment Strategies and Coverage Implications

The Clinical and Economic Burden of SPMS

Determining SPMS as Biological Instead of Classification

Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of Ways

Biomarkers Used to Detect Secondary Progressive MS Needs Improvement for the Care of Patients

Defining active SPMS

How Patients Present SPMS, How to Act on it

The Struggle of Making an Effective SPMS Treatment Early on

Unmet Needs for All and Most Vulnerable Secondary Progressive MS Patients